Impax, Medicis Clear Up Acne Patent Dispute

Law360, New York (December 2, 2008, 12:00 AM EST) -- Impax Laboratories Inc. will be able to move forward with marketing a generic version of the acne medication Solodyn now that the company has resolved its patent battle with Medicis Pharmaceutical Corp.

The companies said Monday they had reached a settlement and license agreement, which ends litigation over Medicis’ patent covering Solodyn and allows Impax to launch a generic version of the drug no later than November 2011. Once Impax starts selling the drug, it may be required to pay Medicis a royalty fee.

The deal...
To view the full article, register now.